Department of Pharmacy, Changzheng Hospital, Naval Medical University, Shanghai, People's Republic of China.
Oncology-Department, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai, People's Republic of China.
Drug Des Devel Ther. 2024 Mar 21;18:881-897. doi: 10.2147/DDDT.S446336. eCollection 2024.
The aim of this study was to verify the effectiveness and explore the mechanism of Chaihu-Guizhi-Ganjiang decoction (CGGD) in the treatment of chronic non-atrophic gastritis (CNAG) with gallbladder heat and spleen cold syndrome (GHSC) by metabolomics based on UHPLC-Q-TOF/MS.
An observational controlled before-after study was conducted to verify the effectiveness of CGGD in the treatment of CNAG with GHSC from January to June 2023, enrolling 27 patients, who took CGGD for 28 days. 30 healthy volunteers were enrolled as the controls. The efficacy was evaluated by comparing the traditional Chinese medicine (TCM) syndrome and CNAG scores, and clinical parameters before and after treatment. The plasma levels of hormones related to gastrointestinal function were collected by ELISA. The mechanisms of CGGD in the treatment of CNAG with GHSC were explored using a metabolomic approach based on UHPLC-Q-TOF/MS.
Patients treated with CGGD experienced a statistically significant improvement in TCM syndrome and CNAG scores (p < 0.01). CGGD treatment evoked the concentration alteration of 15 biomarkers, which were enriched in the glycerophospholipid metabolism, and branched-chain amino acids biosynthesis pathways. Moreover, CGGD treatment attenuated the abnormalities of the gastrointestinal hormone levels and significantly increased the pepsinogen level.
It was the first time that this clinical trial presented detailed data on the clinical parameters that demonstrated the effectiveness of CGGD in the treatment of CNAG with GHSC patients. This study also provided supportive evidence that CNAG with GHSC patients were associated with disturbed branched-chain amino acid metabolism and glycerophospholipid levels, suggesting that CNAG treatment based on TCM syndrome scores was reasonable and also provided a potential pharmacological mechanism of action of CGGD.
本研究旨在通过基于 UHPLC-Q-TOF/MS 的代谢组学方法,验证柴胡桂枝干姜汤(CGGD)治疗胆热脾寒型慢性非萎缩性胃炎(CNAG)的有效性,并探讨其作用机制。
采用观察性对照前后研究,于 2023 年 1 月至 6 月,纳入 27 例胆热脾寒型 CNAG 患者,采用 CGGD 治疗 28 天,验证 CGGD 的疗效。以 30 例健康志愿者作为对照。通过比较治疗前后中医证候和 CNAG 评分及临床参数来评估疗效。采用 ELISA 法收集与胃肠功能相关的激素的血浆水平。采用基于 UHPLC-Q-TOF/MS 的代谢组学方法探讨 CGGD 治疗胆热脾寒型 CNAG 的作用机制。
CGGD 治疗后患者中医证候和 CNAG 评分均有统计学意义的改善(p < 0.01)。CGGD 治疗引起了 15 种生物标志物的浓度变化,这些标志物富集在甘油磷脂代谢和支链氨基酸生物合成途径中。此外,CGGD 治疗可改善胃肠激素水平异常,显著提高胃蛋白酶原水平。
本临床试验首次提供了详细的临床参数数据,证明了 CGGD 治疗胆热脾寒型 CNAG 的有效性。本研究还提供了支持证据,表明胆热脾寒型 CNAG 患者与支链氨基酸代谢和甘油磷脂水平紊乱有关,提示基于中医证候评分的 CNAG 治疗是合理的,也为 CGGD 的潜在药理作用机制提供了依据。